



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	Application Number	10/735,188
	Filing Date	12/12/2003
	First Named Inventor	Stamatas
	Group Art Unit	
	Examiner Name	
	Attorney Docket Number	J&J-5092

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
/ASJ/		Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. <i>Proc Natl Acad Sci U S A</i> 81(2):583-587, 1984.	
		Doukas AG, Soukos NS, Babusis S, Appa Y, Kollias N: Fluorescence excitation spectroscopy for the measurement of epidermal proliferation. <i>Photochem Photobiol</i> 74(1):96-102., 2001.	
		Gillies R, Zonios G, Anderson RR, Kollias N: Fluorescence excitation spectroscopy provides information about human skin in vivo. <i>J Invest Dermatol</i> 115(4):704-707, 2000.	
		Glueck J. The Climate of Tucson, Arizona. NOAA Technical Memorandum NWS WR-249, Western Region, National Weather Service Office, National Oceanic and Atmospheric Administration, 1997.	
		Hornel SE, Eyre DR: Collagen in the ageing human intervertebral disc: an increase in covalently bound fluorophores and chromophores. <i>Biochim Biophys Acta</i> 1078(2):243-250, 1991.	
		Kato Y, Kawakishi S, Aoki T, Itakura K, Osawa T: Oxidative modification of tryptophan residues exposed to peroxynitrite. <i>Biochem Biophys Res Commun</i> 234(1):82-84, 1997.	
		Kollias N, Gillies R, Moran M, Kochevar IE, Anderson RR: Endogenous skin fluorescence includes bands that may serve as quantitative markers of aging and photoaging. <i>J Invest Dermatol</i> 111(5):776-780, 1998.	
		Leffell DJ, Stetzel ML, Milstone LM, Deckelbaum LI: In vivo fluorescence of human skin. A potential marker of photoaging. <i>Arch Dermatol</i> 124(10):1514-1518, 1988.	
		Monnier VM, Cerami A: Non-enzymatic glycosylation and browning of proteins in diabetes. <i>Clin Endocrinol Metab</i> 11(2):431-452, 1982.	
		Bellmunt MJ, Portero M, Pamplona R, Muntaner M, Prat J: Age-related fluorescence in rat lung collagen. <i>Lung</i> 173(3):177-185, 1995.	
		Brancalion L, Durkin AJ, Tu JH, Menaker G, Fallon JD, Kollias N: In vivo fluorescence spectroscopy of nonmelanoma skin cancer. <i>Photochem Photobiol</i> 73(2):178-83., 2001	
		Tian, WD, Anderson, R.R., Drake, L.A., Kollias, N., Noninvasive Monitoring of Treatment Related Changes in Psoriatic Plaques Using Fluorescence Excitation and Diffuse Reflectance Spectroscopy, Biomedical Optical Spectroscopy and Diagnostics, 1998 pp. 113-115.	
		Gonzalez, S., Zonios, G., Nguyen, B.C., Gillies, R. Kollias, N. Endogenous Skin Fluorescence is a Good Marker for Objective Evaluation of Comedolysis, The Society for Investigative Dermatology, Inc. 2000, pp. 100-105.	
		Kollias, N. and Stamatas, G.N. Optical Non-Invasive Approaches to Diagnosis of Skin Diseases, The Society for Investigative Dermatology, Inc. 2002, pp. 64-75.	
		Brancalion L, Lin G, Kollias N: The in vivo fluorescence of tryptophan moieties in human skin increases with UV exposure and is a marker for epidermal proliferation. <i>J Invest Dermatol</i> 113(6):977-982, 1999.	

Examiner Signature	/Ashish Jasani/	Date Considered	03/22/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/735,188
Filing Date	12/12/2003
First Named Inventor	Stamatas
Group Art Unit	
Examiner Name	
Attorney Docket Number	J&J-5092

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ASJ/		Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR: Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. <i>N Engl J Med</i> 314(7):403-408, 1986.	
		Na R, Stender IM, Henriksen M, Wulf HC: Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. <i>J Invest Dermatol</i> 116(4):536-540, 2001.	
		Njoroge FG, Fernandes AA, Monnier VM: Mechanism of formation of the putative advanced glycosylation end product and protein cross-link 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole. <i>J Biol Chem</i> 263(22):10646-10652, 1988.	
		Odetti P, Pronzato MA, Noberasco G, et al.: Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. <i>Lab Invest</i> 70(1):61-67, 1994.	
		Odetti PR, Borgoglio A, Rolandi R: Age-related increase of collagen fluorescence in human subcutaneous tissue. <i>Metabolism</i> 41(6):655-658, 1992.	
		Pongor S, Ulrich PC, Bencsath FA, Cerami A: Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. <i>Proc Natl Acad Sci U S A</i> 81(9):2684-2688, 1984.	
		Reihnsner R, Melling M, Pfeiler W, Menzel EJ: Alterations of biochemical and two-dimensional biomechanical properties of human skin in diabetes mellitus as compared to effects of in vitro non-enzymatic glycation. <i>Clin Biomech (Bristol, Avon)</i> 15(5):379-86., 2000.	
		Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. <i>J Biol Chem</i> 264(36):21597-21602, 1989.	
		Shaklai N, Garlick RL, Bunn HF: Nonenzymatic glycosylation of human serum albumin alters its conformation and function. <i>J Biol Chem</i> 259(6):3812-3817, 1984.	
		Stamatas GN, Wu J, Kollias N: Non-invasive method for quantitative evaluation of exogenous compound deposition on skin. <i>J Invest Dermatol</i> 118(2):295-302, 2002.	
		Tian WD, Gillies R, Brancalion L, Kollias N: Aging and effects of ultraviolet A exposure may be quantified by fluorescence excitation spectroscopy in vivo. <i>J Invest Dermatol</i> 116(6):840-845, 2001.	
		Wolff SP, Dean RT: Glucose autooxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. <i>Bio000000chem J</i> 245(1):243-250, 1987.	
		Wu J, Feld MS, Rava RP: Analytical model for extracting intrinsic fluorescence in turbid media. <i>Applied Optics</i> 32(19):3585-3595, 1993.	
V		Zhang JC, Savage HE, Sacks PG, et al.: Innate cellular fluorescence reflects alterations in cellular proliferation. <i>Lasers Surg Med</i> 20(3):319-31., 1997	

Examiner Signature	/Ashish Jasani/	Date Considered	03/22/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 1

Application Number	10/735,188
Filing Date	12/12/2003
First Named Inventor	Stamatas
Group Art Unit	3736
Examiner Name	
Attorney Docket Number	J&J-5092

U.S. PATENT DOCUMENTS

[illegible]


FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	/Ashish Jasani/	Date Considered	03/22/2007
-----------------------	-----------------	--------------------	------------



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Confirmation Number	2589
Application Number	10/735,188
Filing Date	12/12/2003
First Named Inventor	Georgios Stamatias
Group Art Unit	3736
Examiner Name	
Attorney Docket Number	J&J-5092

U.S. PATENT DOCUMENTS

Exam Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
/ASJ/		4,894,547	A	Leffell et al.	01-16-1990	
↓		5,131,398	A	Alfano et al.	06-21-1992	
↓		6,091,985	A	Alfano et al.	07-18-2000	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ASJ/		TAKEMA ET AL, "Age-related discontinuous changes in the in vivo fluorescence of human facial skin", Journal of Dermatological Science, Vol. 15 (1997) pp 55-58.	

Examiner Signature	/Ashish Jasani/	Date Considered	03/22/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

SUBMISSION UNDER MPEP 609 D Page 1 of 1	Confirmation Number	2589
	Application Number	10/735,188
	Filing Date	12/12/2003
	First Named Inventor	Georgios Stamatas
	Group Art Unit	3736
	Examiner Name	
	Attorney Docket Number	J&J-5092

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign Patent Document			Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁴
			Office ³	Number ⁴	Kind Code ³		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials [*]	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/ASJ/		European Search Report dated March 23, 2005, for corresponding EP application 04257677.7.	

Examiner Signature	/Ashish Jasani/	Date Considered	03/22/2007
-----------------------	-----------------	--------------------	------------